http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#Head http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#assertion http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#provenance http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#pubinfo http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#assertion http://purl.obolibrary.org/obo/DOID_9700 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9700 http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00218 http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#association http://www.w3.org/2000/01/rdf-schema#label moxifloxacin ophthalmic solution usp 5 is a topical fluoroquinolone anti infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms corynebacterium species micrococcus luteus staphylococcus aureus staphylococcus epidermidis staphylococcus haemolyticus staphylococcus hominis staphylococcus warneri streptococcus pneumoniae streptococcus viridans group acinetobacter lwoffii haemophilus influenzae haemophilus parainfluenzae chlamydia trachomatis efficacy for this organism was studied in fewer than 1 infections 1 moxifloxacin ophthalmic solution usp 5 is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms corynebacterium species micrococcus luteus staphylococcus aureus staphylococcus epidermidis staphylococcus haemolyticus staphylococcus hominis staphylococcus warneri streptococcus pneumoniae streptococcus viridans group acinetobacter lwoffii haemophilus influenzae haemophilus parainfluenzae chlamydia trachomatis efficacy for this organism was studied in fewer than 1 infections http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00218 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#provenance http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#pubinfo http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#sig http://purl.org/nanopub/x/hasSignature Ws86x9F1/FxtPC69BLhSEnVPhIvTPC4QBPnmTqS85GjT8gp/yDrlyGulZXl4XBQ+GJDrVE+aWb//fG43U7TevFtUNFWsaCwmSuydDPzP+GYXurSjiRFymzLJ1U+4kXaH63jcvU/Y9gVhlH3f2t+gl9FOQaprHISDz2G6hMO3afw= http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0 http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0 http://purl.org/dc/terms/created 2021-06-30T09:07:00.804+02:00 http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RApMpr1fXbRIeuWoRGMcYTbJ6GOB2wH-Imn6t8Pd51ZV0 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs